MEDICINA
Departamento
Hadassah Medical Center
Jerusalén, IsraelPublicaciones en colaboración con investigadores/as de Hadassah Medical Center (19)
2023
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
-
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Seminars in Hematology
2022
-
A Score to Assess Mortality After Percutaneous Mitral Valve Repair
Journal of the American College of Cardiology, Vol. 79, Núm. 6, pp. 562-573
-
Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction
European heart journal, Vol. 43, Núm. 7, pp. 641-650
-
Prognostic Impact of Nutritional Status After Transcatheter Edge-to-Edge Mitral Valve Repair: The MIVNUT Registry
Journal of the American Heart Association, Vol. 11, Núm. 20
2021
-
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255
-
Safety and feasibility of mitraclip implantation in patients with acute mitral regurgitation after recent myocardial infarction and severe left ventricle dysfunction
Journal of Clinical Medicine, Vol. 10, Núm. 9
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
-
Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis
JACC: Cardiovascular Interventions, Vol. 14, Núm. 1, pp. 1-11
-
Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry)
Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 6, pp. 1259-1267
2020
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2017
-
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367
2016
-
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Blood, Vol. 128, Núm. 9, pp. 1174-1180
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Drugs, Vol. 76, Núm. 8, pp. 853-867
2015
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152
2014
-
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT
Bone marrow transplantation, Vol. 49, Núm. 9, pp. 1170-1175
-
International Myeloma Working Group recommendations for global myeloma care
Leukemia, Vol. 28, Núm. 5, pp. 981-992
2011
-
Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients
Haematologica, Vol. 96, Núm. 8, pp. 1231-1235